Indication intelligence, analysis and sector perception

Alnylam Pharmaceuticals (ALNY) priced 5 M share offering at $77.50

January 15, 2019 8:11pm

ALNY closed down -$3.57 or -4.25% to $80.45 after closing down -$5.10 on Monday

The gross proceeds to ALNY from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $387.5 M.

BUY

Stats:

Shares outsyanding: 101.03 M

Float: 89.53 M

Shares short (12/30/18): 13.38%

Current cash position: $1.24 B

Debt: $30 M

Revenue: $91.81 M

Revenue per share: $0.92

%0 day moving average: $76.39

200 day moving average: $76.39

% held by insiders: 11.36%

% held by institutions: 90.57%

The offering is expected to close on or about 1/17/19, subject to the satisfaction of customary closing conditions.

Alnylam has also granted the underwriter a 30-day option to purchase up to an additional 750 K shares of its common stock solely to cover over-allotments. All of the shares in the offering are to be sold by Alnylam.

Barclays Capital Inc. is acting as sole book-running manager for the offering.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

4 hours 32 min ago
RegMed Investors’ (RMi) pre-open: short week, even shorter fuse with downbeat open numbers

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.